NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...

Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board DirectorSeasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ...

Maternal health in pregnancy is associated with offspring autism, and these associations are largely attributed to familial ...

CEOs emphasize the need to stay nimble and rethink supply chains as barriers to trade are erected in an increasingly ...

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

In the past week, a Boston biotech led by longtime industry CEO Harvey Berger said it plans to shut down, while another ...

Patients with celiac disease have double the incidence rate of chronic liver disease compared with those without this ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

The Philippine Medical Association (PMA) has urged President Marcos to intervene and expedite the approval of new-generation ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.